• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体重指数对糖尿病患者经皮冠状动脉介入治疗长期结局的影响:一项回顾性队列研究。

Impact of body mass index on long-term outcomes in patients undergoing percutaneous coronary intervention stratified by diabetes mellitus: a retrospective cohort study.

机构信息

Medical Big Data Research Center, Medical Innovation Research Division of Chinese, PLA General Hospital, 28 Fuxing RD, Beijing, 100853, China.

Graduate School of Chinese, PLA General Hospital, Beijing, 100853, China.

出版信息

BMC Cardiovasc Disord. 2024 Feb 16;24(1):113. doi: 10.1186/s12872-024-03770-w.

DOI:10.1186/s12872-024-03770-w
PMID:38365597
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10874050/
Abstract

BACKGROUND

Patients with diabetes mellitus (DM) caused by obesity have increased in recent years. The impact of obesity on long-term outcomes in patients undergoing percutaneous coronary intervention (PCI) with or without DM remains unclear.

METHODS

We retrospectively analysed data from 1918 patients who underwent PCI. Patients were categorized into four groups based on body mass index (BMI, normal weight: BMI < 25 kg/m; overweight and obese: BMI ≥ 25 kg/m) and DM status (presence or absence). The primary endpoint was the occurrence of major adverse cardiac and cerebrovascular events (MACCE; defined as all-cause death, myocardial infarction, stroke, and unplanned repeat revascularization).

RESULTS

During a median follow-up of 7.0 years, no significant differences in MACCE, myocardial infarction, or stroke were observed among the four groups. Overweight and obese individuals exhibited lower all-cause mortality rates compared with normal-weight patients (without DM: hazard ratio [HR]: 0.54, 95% confidence interval [CI]: 0.37 to 0.78; with DM: HR: 0.57, 95% CI: 0.38 to 0.86). In non-diabetic patients, the overweight and obese group demonstrated a higher risk of unplanned repeat revascularization than the normal-weight group (HR:1.23, 95% CI:1.03 to 1.46). After multivariable adjustment, overweight and obesity were not significantly associated with MACCE, all-cause death, myocardial infarction, stroke, or unplanned repeat revascularization in patients with and without diabetes undergoing PCI.

CONCLUSION

Overweight and obesity did not demonstrate a significant protective effect on long-term outcomes in patients with and without diabetes undergoing PCI.

摘要

背景

近年来,由肥胖引起的糖尿病(DM)患者有所增加。肥胖对接受经皮冠状动脉介入治疗(PCI)的患者(无论是否患有糖尿病)的长期结局的影响尚不清楚。

方法

我们回顾性分析了 1918 名接受 PCI 的患者的数据。根据体重指数(BMI,正常体重:BMI<25kg/m;超重和肥胖:BMI≥25kg/m)和 DM 状态(存在或不存在),将患者分为四组。主要终点是主要不良心脏和脑血管事件(MACCE;定义为全因死亡、心肌梗死、卒中和计划外再次血运重建)的发生。

结果

在中位随访 7.0 年期间,四组之间在 MACCE、心肌梗死或卒中等方面无显著差异。超重和肥胖患者的全因死亡率低于正常体重患者(无糖尿病:风险比[HR]:0.54,95%置信区间[CI]:0.37 至 0.78;有糖尿病:HR:0.57,95% CI:0.38 至 0.86)。在非糖尿病患者中,超重和肥胖组计划外再次血运重建的风险高于正常体重组(HR:1.23,95% CI:1.03 至 1.46)。在多变量调整后,超重和肥胖与接受和不接受 PCI 的糖尿病患者的 MACCE、全因死亡、心肌梗死、卒中和计划外再次血运重建均无显著相关性。

结论

在接受和不接受 PCI 的糖尿病患者中,超重和肥胖对长期结局没有显著的保护作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fbd/10874050/13f1907fe22a/12872_2024_3770_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fbd/10874050/5c3099e54584/12872_2024_3770_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fbd/10874050/13f1907fe22a/12872_2024_3770_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fbd/10874050/5c3099e54584/12872_2024_3770_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fbd/10874050/13f1907fe22a/12872_2024_3770_Fig2_HTML.jpg

相似文献

1
Impact of body mass index on long-term outcomes in patients undergoing percutaneous coronary intervention stratified by diabetes mellitus: a retrospective cohort study.体重指数对糖尿病患者经皮冠状动脉介入治疗长期结局的影响:一项回顾性队列研究。
BMC Cardiovasc Disord. 2024 Feb 16;24(1):113. doi: 10.1186/s12872-024-03770-w.
2
Staged complete revascularization or culprit-only percutaneous coronary intervention for multivessel coronary artery disease in patients with ST-segment elevation myocardial infarction and diabetes.ST 段抬高型心肌梗死合并糖尿病患者多支冠状动脉病变行分期完全血运重建或罪犯血管单纯经皮冠状动脉介入治疗。
Cardiovasc Diabetol. 2019 Sep 17;18(1):119. doi: 10.1186/s12933-019-0923-0.
3
High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort.伴有 2 型糖尿病的高纤维蛋白原/白蛋白比值与经皮冠状动脉介入治疗患者的不良预后相关:来自大型队列的 5 年研究结果。
Cardiovasc Diabetol. 2022 Mar 21;21(1):46. doi: 10.1186/s12933-022-01477-w.
4
Association between body mass index and clinical outcomes after new-generation drug-eluting stent implantation: Korean multi-center registry data.体重指数与新一代药物洗脱支架植入术后临床结局的关系:韩国多中心注册数据。
Atherosclerosis. 2018 Oct;277:155-162. doi: 10.1016/j.atherosclerosis.2018.08.047. Epub 2018 Aug 31.
5
Significance of diabetes mellitus status in patients undergoing percutaneous left main coronary artery intervention.糖尿病患者行经皮左主干冠状动脉介入治疗的意义。
Catheter Cardiovasc Interv. 2024 Oct;104(4):723-732. doi: 10.1002/ccd.31179. Epub 2024 Aug 17.
6
Impact of body mass index on long-term outcomes in Japanese patients following percutaneous coronary intervention: The Juntendo PCI Registry.体重指数对日本经皮冠状动脉介入治疗患者长期结局的影响:Juntendo PCI 注册研究。
J Cardiol. 2018 Sep;72(3):208-214. doi: 10.1016/j.jjcc.2018.02.007. Epub 2018 Mar 14.
7
Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3 years study from China.中国一项平均随访 6.3 年的研究:糖尿病合并三支血管病变患者不同治疗策略的真实世界结局。
Cardiovasc Diabetol. 2021 Jan 11;20(1):16. doi: 10.1186/s12933-020-01193-3.
8
Impact of diabetes on long-term outcomes of bifurcation percutaneous coronary intervention. An analysis from the BIFURCAT registry.糖尿病对分叉经皮冠状动脉介入治疗长期结局的影响。来自 BIFURCAT 注册研究的分析。
Catheter Cardiovasc Interv. 2023 Oct;102(4):620-630. doi: 10.1002/ccd.30802. Epub 2023 Sep 5.
9
Impact of 3-dimensional bifurcation angle on 5-year outcome of patients after percutaneous coronary intervention for left main coronary artery disease: a substudy of the SYNTAX trial (synergy between percutaneous coronary intervention with taxus and cardiac surgery).三维分叉角度对左主干冠状动脉疾病经皮冠状动脉介入治疗后 5 年预后的影响:SYNTAX 试验(紫杉醇药物洗脱支架与心脏搭桥术的联合治疗)的一项亚组研究。
JACC Cardiovasc Interv. 2013 Dec;6(12):1250-60. doi: 10.1016/j.jcin.2013.08.009.
10
Long-Term Safety and Efficacy of Staged Percutaneous Coronary Intervention for Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Disease.ST 段抬高型心肌梗死合并多支血管病变患者分期经皮冠状动脉介入治疗的长期安全性和疗效。
Am J Cardiol. 2019 Aug 1;124(3):334-342. doi: 10.1016/j.amjcard.2019.04.048. Epub 2019 May 8.

引用本文的文献

1
Body Mass Index and 10-Year Clinical Outcomes After Percutaneous Coronary Intervention-Interaction with Age, Sex, Diabetic Status and Clinical Presentation.经皮冠状动脉介入治疗后的体重指数与10年临床结局——与年龄、性别、糖尿病状态及临床表现的相互作用
J Clin Med. 2025 Feb 20;14(5):1413. doi: 10.3390/jcm14051413.
2
A sex-disaggregated analysis of the prognostic value of lean type 2 diabetes mellitus in the adult population with acute myocardial infarction.成年急性心肌梗死患者中瘦型2型糖尿病预后价值的性别分层分析
Cardiovasc Diabetol. 2025 Feb 7;24(1):59. doi: 10.1186/s12933-024-02552-0.
3
Impact of BMI on Recovery and Quality of Life Post-Revascularization in Peripheral Arterial Disease Patients.

本文引用的文献

1
Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates.基于 2020 年人口普查估计数的美国心血管疾病预测。
J Am Coll Cardiol. 2022 Aug 9;80(6):565-578. doi: 10.1016/j.jacc.2022.05.033.
2
Validation of the obesity paradox by body mass index and waist circumference in patients undergoing percutaneous coronary intervention.经皮冠状动脉介入治疗患者中通过体重指数和腰围验证肥胖悖论。
Int J Obes (Lond). 2022 Oct;46(10):1840-1848. doi: 10.1038/s41366-022-01163-7. Epub 2022 Jul 28.
3
Relationship of body mass index to clinical outcomes after percutaneous coronary intervention.
体重指数对周围动脉疾病患者血运重建术后恢复及生活质量的影响。
Med Sci Monit. 2024 Dec 20;30:e946793. doi: 10.12659/MSM.946793.
4
Percutaneous Coronary Interventions with Sirolimus-Eluting Alex Plus Stents in Patients with or without Diabetes: 4-Year Results.使用西罗莫司洗脱Alex Plus支架对糖尿病或非糖尿病患者进行经皮冠状动脉介入治疗:4年结果
J Cardiovasc Dev Dis. 2024 May 22;11(6):160. doi: 10.3390/jcdd11060160.
体重指数与经皮冠状动脉介入治疗后临床结局的关系。
Eur J Clin Invest. 2022 Aug;52(8):e13789. doi: 10.1111/eci.13789. Epub 2022 Apr 18.
4
Epidemiology and determinants of obesity in China.中国肥胖症的流行病学及决定因素。
Lancet Diabetes Endocrinol. 2021 Jun;9(6):373-392. doi: 10.1016/S2213-8587(21)00045-0.
5
Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction.多支血管 PCI 血运重建:以血流储备分数(FFR)或血管造影为指导治疗心肌梗死。
N Engl J Med. 2021 Jul 22;385(4):297-308. doi: 10.1056/NEJMoa2104650. Epub 2021 May 16.
6
Body mass index and all-cause mortality in patients with percutaneous coronary intervention: A dose-response meta-analysis of obesity paradox.体重指数与经皮冠状动脉介入治疗患者的全因死亡率:肥胖悖论的剂量-反应荟萃分析。
Obes Rev. 2021 Feb;22(2):e13107. doi: 10.1111/obr.13107. Epub 2020 Jul 20.
7
Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.ST段抬高型心肌梗死患者直接经皮冠状动脉介入治疗后无复流现象的预测
Medicine (Baltimore). 2020 Jun 26;99(26):e20152. doi: 10.1097/MD.0000000000020152.
8
2. Classification and Diagnosis of Diabetes: .2. 糖尿病的分类和诊断: 。
Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31. doi: 10.2337/dc20-S002.
9
Association of Body Mass Index and Extreme Obesity With Long-Term Outcomes Following Percutaneous Coronary Intervention.体重指数与极重度肥胖与经皮冠状动脉介入治疗后长期预后的相关性。
J Am Heart Assoc. 2019 Nov 5;8(21):e012860. doi: 10.1161/JAHA.119.012860. Epub 2019 Oct 25.
10
Fourth Universal Definition of Myocardial Infarction (2018).心肌梗死的第四次全球定义(2018年)。
Circulation. 2018 Nov 13;138(20):e618-e651. doi: 10.1161/CIR.0000000000000617.